Although HDAC inhibitors have shown positive effects in preclinical models of cardiovascular diseases, cardiac side effects such as, QTc prolongation, hypotension, myocardial infarction and so forth were reported in cancer patients upon HDAC inhibitor treatment [143], therefore HDAC inhibitors were not evaluated in cardiovascular patients. Here, HDAC9 is linked to myocardial infarction.